Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01926626 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
A Phase 2 study of Nicotine Dependence, sponsored by Jed E. Rose.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 3
- Study locations
NCT01926626: Completed Phase 2 study of Nicotine Dependence, sponsored by Jed E. Rose.
NCT01926626 is a Phase 2 study of Nicotine Dependence that has completed, run by Jed E. Rose. The registered enrollment target is 76 participants, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (59% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01926626, a Phase 2 study of Nicotine Dependence, has completed, sponsored by Jed E. Rose.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 3
- Study locations
Study Summary
The proposed study will assess the efficacy of moclobemide, a selective, reversible MAO-A inhibitor, in facilitating smoking cessation in treatment-seeking female smokers. This rationale is based on several findings from previous work: 1) cigarette smoke contains constituents that inhibit both forms of the enzyme monoamine oxidase (MAO-A and MAO-B); 2) that severity of depression symptoms after smoking abstinence is correlated with the level of MAO-A inhibition previously obtained from smoking; 3) moclobemide, an MAO-A inhibitor was found efficacious in a smoking cessation treatment trial (Berlin et al., 1995); and 4) women show a greater association between smoking and depression than men and women smokers in our previous trials report smoking to alleviate symptoms of depression to a greater extent than men.
Primary Outcome
Number of participants who reported continuous four-week abstinence from smoking (weeks 6-10 post target quit date), confirmed by expired air carbon monoxide (CO).
Conditions Studied
Interventions
- DRUG Nicotine Patch
- DRUG Moclobemide
Study Locations (3)
North Carolina
- Duke Center for Smoking Cessation - Charlotte
- Duke Center forSmoking Cessation - Durham
- Duke Center for Smoking Cessation - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
What the finished NCT01926626 record still lists
NCT01926626 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Nicotine Dependence appearing as the primary indexed condition, and to 2 interventions - of which Nicotine Patch is the first listed.
NCT01926626 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01926626 about?
NCT01926626 is a clinical study titled "Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers". The proposed study will assess the efficacy of moclobemide, a selective, reversible MAO-A inhibitor, in facilitating smoking cessation in treatment-seeking female smokers. This rationale is based on several findings from previous work: 1) cigarette smoke contains constituents that inhibit both forms...
What is the current status of trial NCT01926626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2013-09. Estimated completion is 2014-10.
What conditions does trial NCT01926626 study?
This clinical trial studies the following conditions: Nicotine Dependence.
What interventions are being tested in trial NCT01926626?
The interventions under investigation include: Nicotine Patch (DRUG), Moclobemide (DRUG).
Who is sponsoring clinical trial NCT01926626?
This trial is sponsored by Jed E. Rose, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01926626 being conducted?
This trial has 3 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01926626's enrollment target sits among peer trials
76 44th of 67 higher than 23 of 67 other Nicotine Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nicotine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of Varenicline for E-cigarette Cessation
RECRUITING · Phase 2
-
Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity
COMPLETED · Phase 2
-
N-acetylcysteine for Tobacco Use Disorder
COMPLETED · Phase 2
-
Targeted Interventions for Weight-Concerned Smokers
COMPLETED · Phase 2
-
Adaptive Pharmacotherapy for Smoking Cessation
COMPLETED · Phase 2
-
E-cigarette Nicotine Study
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia